Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATECNASDAQ:ATRCNASDAQ:CSIINASDAQ:NUVA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATECAlphatec$12.67+3.8%$10.52$4.88▼$12.82$1.85B1.062.04 million shs1.54 million shsATRCAtriCure$31.81+2.6%$32.59$18.94▼$43.11$1.57B1.57653,565 shs596,072 shsCSIICardiovascular Systems$20.00$19.98$12.26▼$20.57$843.96M0.74765,906 shs4,300 shsNUVANuVasive$39.75$39.64$35.17▼$49.53$2.08B1.071.16 million shsN/A7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATECAlphatec+3.68%+5.76%+29.95%+15.71%+9.98%ATRCAtriCure+2.65%+9.43%-0.81%-23.37%+42.65%CSIICardiovascular Systems0.00%0.00%0.00%0.00%0.00%NUVANuVasive0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATECAlphatec4.0701 of 5 stars3.41.00.03.32.74.20.6ATRCAtriCure3.6755 of 5 stars4.53.00.00.03.02.50.6CSIICardiovascular SystemsN/AN/AN/AN/AN/AN/AN/AN/ANUVANuVasiveN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATECAlphatec 2.89Moderate Buy$17.8941.19% UpsideATRCAtriCure 3.00Buy$50.6759.28% UpsideCSIICardiovascular Systems 0.00N/AN/AN/ANUVANuVasive 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ATEC, ATRC, NUVA, and CSII Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/2/2025ATECAlphatecPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$13.00 ➝ $15.005/2/2025ATECAlphatecNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.004/30/2025ATRCAtriCureJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$60.00 ➝ $60.004/30/2025ATRCAtriCureUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$60.00 ➝ $58.004/30/2025ATRCAtriCureNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$51.00 ➝ $44.004/14/2025ATECAlphatecHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.003/28/2025ATRCAtriCureCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$66.00 ➝ $52.003/27/2025ATRCAtriCureBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/27/2025ATRCAtriCureJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$51.00 ➝ $46.003/27/2025ATRCAtriCureNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$51.00 ➝ $51.003/21/2025ATRCAtriCureNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$51.00 ➝ $51.00(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATECAlphatec$642.27M2.88N/AN/A$0.57 per share22.23ATRCAtriCure$480.08M3.28N/AN/A$9.46 per share3.36CSIICardiovascular Systems$239.84M3.52N/AN/A$6.12 per share3.27NUVANuVasive$1.23B1.70$4.96 per share8.01$17.02 per share2.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATECAlphatec-$186.64M-$1.15N/AN/AN/A-31.06%-541.39%-22.99%7/30/2025 (Estimated)ATRCAtriCure-$44.70M-$0.81N/AN/AN/A-9.61%-6.80%-5.19%7/29/2025 (Estimated)CSIICardiovascular Systems-$36.93M-$0.97N/AN/AN/A-15.79%-15.39%-11.93%N/ANUVANuVasive$40.41M$0.5079.5015.35N/A2.32%12.17%4.88%N/ALatest ATEC, ATRC, NUVA, and CSII EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025Q1 2025ATECAlphatec-$0.12-$0.35-$0.23-$0.35$167.57 million$169.18 million4/29/2025Q1 2025ATRCAtriCure-$0.25-$0.14+$0.11-$0.14$122.92 million$123.62 million2/26/2025Q4 2024ATECAlphatec-$0.19-$0.23-$0.04-$0.23$172.74 million$176.79 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATECAlphatecN/AN/AN/AN/AN/AATRCAtriCureN/AN/AN/AN/AN/ACSIICardiovascular SystemsN/AN/AN/AN/AN/ANUVANuVasiveN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATECAlphatec30.212.321.15ATRCAtriCure0.133.652.62CSIICardiovascular Systems0.086.044.92NUVANuVasive0.501.250.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATECAlphatec66.35%ATRCAtriCure99.11%CSIICardiovascular Systems86.61%NUVANuVasiveN/AInsider OwnershipCompanyInsider OwnershipATECAlphatec20.90%ATRCAtriCure3.50%CSIICardiovascular Systems3.80%NUVANuVasive0.53%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATECAlphatec700146.17 million109.48 millionOptionableATRCAtriCure1,05049.51 million47.32 millionOptionableCSIICardiovascular Systems78042.20 million40.59 millionOptionableNUVANuVasive3,00052.45 million52.17 millionOptionableATEC, ATRC, NUVA, and CSII HeadlinesRecent News About These CompaniesGlobus Medical Q1 sales dip slightly: 5 notesMay 10 at 3:49 AM | beckersspine.comVerdict Against NuVasive in Patent DisputeMay 9, 2025 | ryortho.com5 patent battles to knowMay 2, 2025 | beckersasc.comNuVasive infringed surgeon’s spine patents, jury saysApril 24, 2025 | beckersspine.comArtificial Tendons and Ligaments Market Expected to Hit USD 2.7 Billion by 2035 with a Remarkable 10.46% CAGRApril 23, 2025 | biznes.newseria.plNuVasive Infringes Surgeon’s Spinal-Screws Patents, Jury SaysApril 22, 2025 | news.bloomberglaw.comSpine company names Keith Valentine CEOApril 11, 2025 | beckersspine.comThe Perils of Procedural Misadventure and Unclear Claim Drafting in Patent LitigationMarch 26, 2025 | jdsupra.comGlobal Medical Handily Beats 2024 Sales EstimatesMarch 14, 2025 | ryortho.comGlobus Medical targets $2.8B-$2.9B revenue in 2025 with Nevro acquisition integrationFebruary 21, 2025 | msn.comGlobus Medical Q4, 2024 sales riseFebruary 20, 2025 | beckersspine.comGlobus Medical: Some Caution After Its Deal For NevroFebruary 16, 2025 | seekingalpha.comFlorida Sales Rep Ordered to Pay $19 millionFebruary 10, 2025 | ryortho.comBTIG maintains $91 target on Globus Medical stock post-acquisitionFebruary 6, 2025 | msn.comGlobus acquisition of Nevro complicates story, says StifelFebruary 6, 2025 | markets.businessinsider.comSMAIO Provides Update on Its Partnership With NuVasive and Confirms Its Strategic Focus on the U.S. MarketJanuary 28, 2025 | uk.finance.yahoo.comNuVasive, SMAIO end orthopedic partnershipJanuary 28, 2025 | beckersspine.comGlobus Medical raises FY24 revenue view to $2.52B from $2.49B-$2.5BJanuary 8, 2025 | markets.businessinsider.comGlobus Medical Stock: Re-Rated After A Solid YearNovember 18, 2024 | seekingalpha.comSurgeons Billed $2 Billion for Unnecessary Spine Surgeries: ReportNovember 14, 2024 | medpagetoday.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATEC, ATRC, NUVA, and CSII Company DescriptionsAlphatec NASDAQ:ATEC$12.67 +0.46 (+3.77%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$12.62 -0.04 (-0.36%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec surface modifications, Calibrate PSX, and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold for ease of handling and better endplate-to-endplate contact; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissues; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.AtriCure NASDAQ:ATRC$31.81 +0.82 (+2.65%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$31.84 +0.04 (+0.11%) As of 04:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.Cardiovascular Systems NASDAQ:CSIICardiovascular Systems, Inc. is a medical device company, which engages in the development and commercialization of solutions for treating vascular and coronary disease. It offers orbital atherectomy systems for both peripheral and coronary commercial applications. The company was founded in 1989 and is headquartered in St. Paul, MN.NuVasive NASDAQ:NUVANuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California. As of September 1, 2023, NuVasive, Inc. operates as a subsidiary of Globus Medical, Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
